Deep Sequencing Reveals Dual Evolution of SARS-CoV-2: Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants

Other authors

Institut Català de la Salut

[Campos C, Colomer Castell S, Esteban JI, Quer J] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Ibañez‐Lligoña M] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Medicine Department, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Gregori J] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Garcia Cehic D] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. [Andrés C, Piñana M, González Sánchez A] Unitat de Virus Respiratoris, Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER of Infectious Diseases (CIBERINFEC) Instituto de Salud Carlos III, Madrid, Spain. [Rando Segura A] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Unitat de Virus Respiratoris, Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Esperalba J, Saubí N] Unitat de Virus Respiratoris, Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Cortese MF] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Tabernero D] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Ferrer R] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pumarola T, Antón A] Unitat de Virus Respiratoris, Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER of Infectious Diseases (CIBERINFEC) Instituto de Salud Carlos III, Madrid, Spain. Microbiology Department, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2025-09-25T07:44:15Z

2025-09-25T07:44:15Z

2025-07

Abstract

Omicron; Deep‐sequencing; Dual evolution


Òmicron; Seqüenciació profunda; Evolució dual


Ómicron; Secuenciación profunda; Evolución dual


SARS-CoV-2 has evolved from early variants dominating the first (B.1.5, B.1.1) and second (B.1.177) pandemic waves, which exhibited a higher frequency of minority mutants with deletions leading to Defective Viral Genomes (DVGs) in the spike region near the S1/S2 cleavage site than the Alpha, Beta, and Delta variants. The emergence of Omicron has significantly altered the dominant variant profile, with Omicron subvariants now representing 100% of circulating viruses. To monitor the evolution and adaptation of Omicron in the human population, a deep-sequencing study was performed in RNA samples of BA.1, BA.1.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and BA.2.86 Omicron subvariants. The findings reveal two occurrences of similar evolutionary patterns within SARS-CoV-2 characterized by a shift from a significant to a very low production of DVGs. This event suggests that DVGs might play a role in the virus's spread and adaptation for persistence in infected humans.


This study was supported by the Centro para el Desarrollo Tecnológico Industrial (CDTI) of the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by the ERDF A way of making Europe; Fondo de Investigación Sanitaria, Spanish Ministry of Economy and Competitiveness (grants FIS PI19/00301, PI19/00533, PI22/00258, PI22/00023, and PI23/01065); CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, ISCIII—CIBER of Infectious Diseases & CIBEREHD, ISCIII—CIBER of Hepatic and Digestive Diseases), Instituto de Salud Carlos III, Ministry of Science and Innovation and the European Union—NextGenerationEU. Research contributions of Wageningen Bioveterinary Research are funded from the ERRAZE (Early Response and Rapid Action Zoonotic Emergencies Program). C.C. received a predoctoral fellowship from the Vall d'Hebron Institute of Research (VHIR). M.I.-L. was supported by a fellowship from the “La Caixa” Foundation (ID 100010434), with code “LCF/BQ/DR23/12000020”. S.C-C. received support from the Spanish Ministry of Education grant FPU21/04150.

Document Type

Article


Published version

Language

English

Publisher

Wiley

Related items

Journal of Medical Virology;97(7)

https://doi.org/10.1002/jmv.70476

info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PID2021-126447OB-I00

info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00301

info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00533

info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F00258

info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F00023

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)